Hoth Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.12.22	Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001 (PR Newswire)
09.11.22	Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
31.10.22	Hoth Reports Positive Biolexa Phase 1b Trial Results In Mild To Moderate Atopic Dermatitis; Stock Up (RTTNews)
31.10.22	HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS (PR Newswire)
24.10.22	Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 (PR Newswire)
20.09.22	Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke (RTTNews)
20.09.22	Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke (PR Newswire)
06.09.22	Hoth: Treatment With HT-004 Significantly Reduces Lung Inflammation In Asthma, Allergy Mouse Model (RTTNews)
06.09.22	Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders (PR Newswire)
12.08.22	Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference (PR Newswire)
12.07.22	Hoth Says HT-ALZ Therapeutic Shows Cognitive Improvements In Alzheimer's Disease Mouse Model (RTTNews)
12.07.22	Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model (PR Newswire)
29.06.22	Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (PR Newswire)
21.06.22	Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis (PR Newswire)
15.06.22	Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022 (PR Newswire)
09.06.22	Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ (PR Newswire)
03.05.22	Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort (PR Newswire)
19.04.22	Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury (PR Newswire)
14.04.22	Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market (PR Newswire)
12.04.22	Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference (PR Newswire)
12.04.22	Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market (PR Newswire)
11.04.22	Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
11.04.22	Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells (PR Newswire)
01.04.22	Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention (PR Newswire)
22.03.22	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance (PR Newswire)
11.03.22	Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis (PR Newswire)
09.02.22	Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients (PR Newswire)
07.02.22	Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference (PR Newswire)
31.01.22	Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board (PR Newswire)
04.01.22	Hoth Therapeutics: HT-ALZ Reduces Circulating Brain Ass In Alzheimer's Disease Mouse Model (RTTNews)
04.01.22	Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease (PR Newswire)
21.12.21	Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis (PR Newswire)
08.12.21	Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics (PR Newswire)
30.11.21	Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way (PR Newswire)
16.11.21	Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT (PR Newswire)
08.11.21	Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic (PR Newswire)
19.10.21	Hoth Therapeutics Extends Partnership Agreement with REPROCELL (PR Newswire)
12.10.21	Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients (PR Newswire)
21.09.21	Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial (PR Newswire)
08.09.21	Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa (PR Newswire)
11.08.21	Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy (PR Newswire)
13.07.21	Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne (PR Newswire)
28.06.21	Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis (PR Newswire)
07.06.21	Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ (PR Newswire)
23.03.21	Hoth: Extremely Positive In Vitro Data Supports HT-002's Antiviral Activity Against SARS-CoV-2 (RTTNews)
13.01.21	FDA Grants Hoth Pre-IND Meeting On Proposed Drug Development Plan For HT-001 Treatment (RTTNews)
06.01.21	MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301 (RTTNews)
31.12.20	Stock Alert: Hoth Therapeutics Surges 50% (RTTNews)
31.12.20	Hoth Therapeutics Inks Production Deal With Tergus Pharma For HT-001 GLP And GMP Materials (RTTNews)
27.08.20	Pre-market Movers In Healthcare Sector: EYPT, CLVS, ABT, VBIV, LPCN... (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	174.30	2.47 %	K V
Sika	233.70	2.23 %	K V
Holcim	91.14	1.47 %	K V
Sonova Hldg	318.40	1.14 %	K V
Logitech Intl	83.14	1.09 %	K V
Part Grp Hldg	1’400.50	-0.25 %	K V
Swisscom	505.50	-0.39 %	K V
Swiss Re	137.70	-0.65 %	K V
Zurich Insur Gr	536.20	-0.70 %	K V
Givaudan	3’857.00	-2.13 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Hoth Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten